---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-088072"
form_type: "8-K"
ticker: "MRKR"
cik: "0001094038"
company_name: "Marker Therapeutics, Inc."
filed_at: "2023-08-07T23:59:59+00:00"
generated_at: "2026-06-12T03:44:53.334426+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Marker Therapeutics reports non-clinical proof-of-concept data for MT-401 OTS, expects first patient treatment H1 2024

## Summary
- Non-clinical data: MT-401 OTS killed AML cells in vitro with 2/8 HLA match, significantly reducing THP-1 cell growth.
- FDA cleared clinical protocol for MT-401 OTS in relapsed/refractory AML; inventory of 8 donor lines established.
- Single donor could treat ~40 patients; product stable >1 year; first patient treatment expected H1 2024.
- OTS strategy aims to reduce manufacturing cost and turnaround time to as little as 72 hours.

## SEC filing metadata
- accession: 0001104659-23-088072
- form_type: 8-K
- ticker: MRKR
- cik: 0001094038
- company_name: Marker Therapeutics, Inc.
- filed_at: 2023-08-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1094038/000110465923088072/0001104659-23-088072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1094038/000110465923088072/tm2320895d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-088072
- JSON: https://secwatch.observer/filing/0001104659-23-088072.json
- Plain text: https://secwatch.observer/filing/0001104659-23-088072.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.